These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 9403512)
1. Sho-saiko-to, a traditional Kampo medicine, enhances the anti-HIV-1 activity of lamivudine (3TC) in vitro. Piras G; Makino M; Baba M Microbiol Immunol; 1997; 41(10):835-9. PubMed ID: 9403512 [TBL] [Abstract][Full Text] [Related]
2. Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients. Kuritzkes DR; Quinn JB; Benoit SL; Shugarts DL; Griffin A; Bakhtiari M; Poticha D; Eron JJ; Fallon MA; Rubin M AIDS; 1996 Aug; 10(9):975-81. PubMed ID: 8853730 [TBL] [Abstract][Full Text] [Related]
3. Is AZT/3TC therapy effective against FIV infection or immunopathogenesis? Arai M; Earl DD; Yamamoto JK Vet Immunol Immunopathol; 2002 Mar; 85(3-4):189-204. PubMed ID: 11943320 [TBL] [Abstract][Full Text] [Related]
4. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC]. Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391 [TBL] [Abstract][Full Text] [Related]
5. In vitro analysis of synergism and antagonism of different nucleoside/nucleotide analogue combinations on the inhibition of human immunodeficiency virus type 1 replication. Perez-Olmeda M; Garcia-Perez J; Mateos E; Spijkers S; Ayerbe MC; Carcas A; Alcami J J Med Virol; 2009 Feb; 81(2):211-6. PubMed ID: 19107982 [TBL] [Abstract][Full Text] [Related]
6. Zidovudine and lamivudine: results of phase III studies. Staszewski S J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S57. PubMed ID: 8595510 [TBL] [Abstract][Full Text] [Related]
7. Retention of marked sensitivity to (S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthiomethyl)-3,4-di hydroquin oxaline-2(1H)-thione (HBY 097) by an azidothymidine (AZT)-resistant human immunodeficiency virus type 1 (HIV-1) strain subcultured in the combined presence of quinoxaline HBY 097 and 2',3'-dideoxy-3'-thiacytidine (lamivudine). Balzarini J; Pelemans H; Riess G; Roesner M; Winkler I; De Clercq E; Kleim JP Biochem Pharmacol; 1998 Mar; 55(5):617-25. PubMed ID: 9515572 [TBL] [Abstract][Full Text] [Related]
9. Three-drug combination of MKC-442, lamivudine and zidovudine in vitro: potential approach towards effective chemotherapy against HIV-1. Piras G; Nakade K; Yuasa S; Baba M AIDS; 1997 Mar; 11(4):469-75. PubMed ID: 9084794 [TBL] [Abstract][Full Text] [Related]
10. A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2',3'-dideoxy-3'-thiacytidine. Kemp SD; Shi C; Bloor S; Harrigan PR; Mellors JW; Larder BA J Virol; 1998 Jun; 72(6):5093-8. PubMed ID: 9573280 [TBL] [Abstract][Full Text] [Related]
11. Zidovudine/lamivudine but not nevirapine in combination with lopinavir/ritonavir decreases subcutaneous adipose tissue mitochondrial DNA. Feeney ER; van Vonderen MG; Wit F; Danner SA; van Agtmael MA; Villarroya F; Domingo P; Capeau J; Reiss P; Mallon PW; AIDS; 2012 Nov; 26(17):2165-74. PubMed ID: 22874517 [TBL] [Abstract][Full Text] [Related]
12. Frequency of Tk and Hprt lymphocyte mutants and bone marrow micronuclei in B6C3F(1)/Tk+/- mice treated neonatally with zidovudine and lamivudine. Von Tungeln LS; Hamilton LP; Dobrovolsky VN; Bishop ME; Shaddock JG; Heflich RH; Beland FA Carcinogenesis; 2002 Sep; 23(9):1427-32. PubMed ID: 12189183 [TBL] [Abstract][Full Text] [Related]
13. Prenatal exposure to anti-HIV drugs: neurobehavioral effects of zidovudine (AZT) + lamivudine (3TC) treatment in mice. Venerosi A; Valanzano A; Alleva E; Calamandrei G Teratology; 2001 Jan; 63(1):26-37. PubMed ID: 11169552 [TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind study of triple nucleoside therapy of abacavir, lamivudine, and zidovudine versus lamivudine and zidovudine in previously treated human immunodeficiency virus type 1-infected children. The CNAA3006 Study Team. Sáez-Llorens X; Nelson RP; Emmanuel P; Wiznia A; Mitchell C; Church JA; Sleasman J; Van Dyke R; Richardson CG; Cutrell A; Spreen W; Hetherington S Pediatrics; 2001 Jan; 107(1):E4. PubMed ID: 11134468 [TBL] [Abstract][Full Text] [Related]
15. [In vitro pharmacodynamics study of an anti-HIV Chinese herbal formulation]. Li ZL; Zeng Y; Su LS; Zhang XM; Shao YM; Zeng X; Wolf H; Zeng Y Yao Xue Xue Bao; 2010 Feb; 45(2):253-6. PubMed ID: 21351436 [TBL] [Abstract][Full Text] [Related]
17. The effects of lamivudine treatment on HIV-1 disease progression are highly correlated with plasma HIV-1 RNA and CD4 cell count. Montaner JS; DeMasi R; Hill AM AIDS; 1998 Mar; 12(5):F23-8. PubMed ID: 9543436 [TBL] [Abstract][Full Text] [Related]
18. Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients. Masquelier B; Neau D; Boucher S; Lavignolle-Aurillac V; Schrive MH; Recordon-Pinson P; Ragnaud JM; Fleury H Antivir Ther; 2006; 11(6):827-30. PubMed ID: 17310827 [TBL] [Abstract][Full Text] [Related]
19. A new antiviral: chimeric 3TC-AZT phosphonate efficiently inhibits HIV-1 in human tissues ex vivo. Vanpouille C; Khandazhinskaya A; Karpenko I; Zicari S; Barreto-de-Souza V; Frolova S; Margolis L; Kochetkov S Antiviral Res; 2014 Sep; 109():125-31. PubMed ID: 25010891 [TBL] [Abstract][Full Text] [Related]
20. Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV. Stürmer M; Staszewski S; Doerr HW Antivir Ther; 2007; 12(5):695-703. PubMed ID: 17713153 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]